SCHEMBL4879063

SCHEMBL4879063

C=CCc1cc(C=O)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 10/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
MAPT P10636 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.40
POLB P06746 3/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
KIF11 P52732 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
PTGS2 P35354 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 2/20 0.35
GABRA1 P14867 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7055923 0.82 KDM4E (0.45) KDM4EALDH1A1L3MBTL1MAPTCYP1A2
SCHEMBL29953151 0.79 ALDH1A1 (0.45) KDM4EALDH1A1CYP1A2POLBMEN1
SCHEMBL27688344 0.79 ALDH1A1 (0.42) KDM4EALDH1A1CYP1A2POLBMEN1
SCHEMBL3035961 0.79 ALDH1A1 (0.45) KDM4EALDH1A1CYP1A2POLBMEN1
SCHEMBL17694445 0.78 KDM4E (0.53) KDM4EALDH1A1MAPTPOLBMEN1
SCHEMBL10490689 0.78 KDM4E (0.42) KDM4EALDH1A1L3MBTL1MAPTCYP1A2
SCHEMBL1002665 0.78 GABRA1 (0.61) KDM4EALDH1A1MAPTLMNAPOLB
SCHEMBL10071819 0.78 KDM4E (0.45) KDM4EALDH1A1L3MBTL1MAPTCYP1A2
SCHEMBL2679167 0.77 ALDH1A1 (0.42) KDM4EALDH1A1CYP1A2POLBMEN1
SCHEMBL4339392 0.77 ALDH1A1 (0.44) KDM4EALDH1A1CYP1A2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors NOVARTIS AG (CH) 2008-06-05 US disclosed
EP-1851208-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS Novartis AG (CH) 2007-11-07 EP disclosed
WO-2006074950-A1 MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132477-A1 Macrocyclic Compounds Useful as Bace Inhibitors BACE1, BACE2, APP KDM4E 3337/4885ALDH1A1 2631/4885L3MBTL1 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.